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Abstract
Angiotensin I-converting enzyme (ACE) inhibitory and hypotensive effects of 7 peptide frac-
tions (Frs) of royal jelly protein hydrolysate (RJPH) were studied in comparison with those of
RJPH alone. Fr 4 and Fr 5 were the highest in ACE inhibitory activity and yield, respectively.
Molecular weights (MWs) of RJPH and Fr 1-Fr 7 were distributed from 100 to 5,000 and those of
Fr 1-Fr 7 increased in order from Fr 1 to Fr 7. RJPH, Fr 3 and Fr 4 at doses of 10, 30 and 100mg/kg
i.v. and Fr 5 and Fr 6 at doses of 30 and 100mg/kg i.v. caused transiently significant hypotensive
effects in spontaneously hypertensive rats (SHR). Fr 3, Fr 4, Fr 5 and Fr 6 at a dose of 1,000mg/kg
also caused significant hypotensive effects 3h, 4-5h, 7-8h and 8h after oral administration in SHR,
respectively. RJPH caused a long-lasting hypotensive effect in proportion to the magnitude of the
MWs of RJPH fractions. The hypotensive pattern of RJPH was similar to the combined pattern
of Fr 3-Fr 6. From these results, it can be concluded that the long-lasting hypotensive effect of
oral administration of RJPH is dependent on the MWs of its ACE inhibitory peptides and the time
required to digest them.
KEYWORDS: royal jelly, peptide, ACE inhibitory activity, hypotensive effect, spontaneously
hypertensive rat
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Angiotensin I-converting enzyme (ACE) inhibitory and hypotensive eﬀects of 7 peptide fractions (Frs) 
of royal jelly protein hydrolysate (RJPH) were studied in comparison with those of RJPH alone.  Fr 4 
and Fr 5 were the highest in ACE inhibitory activity and yield,  respectively.  Molecular weights (MWs) 
of RJPH and Fr 1ﾝFr 7 were distributed from 100 to 5,000 and those of Fr 1ﾝFr 7 increased in order 
from Fr 1 to Fr 7.  RJPH,  Fr 3 and Fr 4 at doses of 10,  30 and 100mg/kg i.v.  and Fr 5 and Fr 6 at 
doses of 30 and 100mg/kg i.v.  caused transiently signiﬁcant hypotensive eﬀects in spontaneously 
hypertensive rats (SHR).  Fr 3,  Fr 4,  Fr 5 and Fr 6 at a dose of 1,000mg/kg also caused signiﬁcant 
hypotensive eﬀects 3h,  4ﾝ5h,  7ﾝ8h and 8h after oral administration in SHR,  respectively.  RJPH 
caused a long-lasting hypotensive eﬀect in proportion to the magnitude of the MWs of RJPH fractions.  
The hypotensive pattern of RJPH was similar to the combined pattern of Fr 3ﾝFr 6.  From these 
results,  it can be concluded that the long-lasting hypotensive eﬀect of oral administration of RJPH is 
dependent on the MWs of its ACE inhibitory peptides and the time required to digest them.
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t is well known that hypertension is a major risk 
factor for cerebral stroke,  heart failure,  acute 
myocardial infarction and diabetic nephropathy.  On 
the other hand,  food products containing sardine 
dipeptide,  lacto-tripeptides,  or dried bonito oligopep-
tides,  all of which exhibit angiotensin I-converting 
enzyme (ACE) inhibitory activity,  have a hypotensive 
eﬀect comparable to that of antihypertensive medica-
tions [1ﾝ3].  Therefore,  the potential use of these 
products to maintain low blood pressure has been 
attracting attention in middle-aged and older people.  
However,  the results of one of the main studies sup-
porting this use of peptide-containing foods have not 
been reproducible.  In the study in question,  the sar-
dine peptide Val-Tyr and the lacto-tripeptide Ile-Pro-
Pro were shown to have hypotensive eﬀects in sponta-
neously hypertensive rats (SHR),  and the lack of 
reproducible results may be related to diﬀerences in 
the methods used to measure blood pressure between 
this and subsequent studies [4].  Currently,  there-
fore,  there is insuﬃcient information on the hypoten-
sive eﬀect of protein hydrolysate in in vivo studies,  
although many studies have shown that some peptides 
had potent ACE inhibitory activity.
　 Royal jelly of the honeybee Apis mellifera L.  is a 
yogurt-like bee milk secreted by worker bees as food 
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for their queen,  and is also used worldwide as a popu-
lar health food [5].  Royal jelly contains various pro-
teins,  including essential amino acids,  sugar,  fatty 
acids and vitamins [6].  Scientiﬁc reports have shown 
that royal jelly exhibits bioactivities such as antitumor 
activity,  a preventive eﬀect against osteoporosis,  and 
amelioration of menopausal disorder [7ﾝ9].  The 
hypotensive eﬀect of royal jelly has recently been 
studied in detail; that is,  11 ACE inhibitory peptides 
have been found in a pepsin/trypsin/chymotrypsin 
hydrolysate of royal jelly protein (RJP),  and the 
hydrolysate decreased blood pressure in SHR [10].  
Recently,  a microbial protease-treated royal jelly 
protein hydrolysate containing ACE inhibitory pep-
tides was shown to decrease blood pressure in SHR 
[11] and in humans [12] with high-normal blood pres-
sure or mild hypertension in a 3-month ingestion test.
　 We have also studied a trypsin-treated royal jelly 
protein hydrolysate (RJPH) desalted by a column 
wash,  which contains many kinds of ACE inhibitory 
peptides [13].  In this study,  we compared the hypo-
tensive eﬀects of 7 peptide fractions separated from 
RJPH with that of RJPH alone in SHR in order to 
investigate the correlation between the hypotensive 
pattern of RJPH and the molecular weight of its pep-
tides.
Materials and Methods
　 Animals and chemicals. Male SHR aged 8ﾝ
10 weeks were purchased from Japan SLC,  Inc.  
(Hamamatsu,  Japan).  All animals were maintained in 
an air-conditioned room with controlled temperature 
(23±2℃) and humidity (30ﾝ80ｵ).  They were housed 
individually in metal cages and kept under a light-dark 
cycle (lights on from 6 : 30 to 18 : 30),  and they were 
fed with normal rat chow (CRF-1; Oriental Yeast Co.,  
Ltd.,  Tokyo,  Japan) and given water ad libitum.  The 
rats were 10ﾝ13 weeks old (body weight 267ﾝ324g).  
All procedures involving animals were performed in 
accordance with the “Standards Relating to the Care 
and Management,  etc.  of Experimental Animals” 
issued by the Prime Ministerʼs Oﬃce,  Japan.  RJP was 
obtained from Yamada Apiculture Center,  Inc.  
(Okayama,  Japan) and Ile-Tyr was from Kokusan 
Chemical Co.,  Ltd.  (Tokyo,  Japan).
　 Preparation of RJPH. RJPH was prepared as 
previously reported [13].  Ethanol-denatured RJP was 
dissolved in 10 volumes of water,  and the solution was 
adjusted to pH 8.0 with 20ｵ sodium hydroxide 
(NaOH) solution at 37℃ and added to 0.25wtｵ 
trypsin (Novozymes A/S,  Bagsvaerd,  Denmark),  and 
reacted for 24h.  This reaction solution was heated at 
100℃ for 30min to inactivate the enzyme,  and then 
adjusted to pH 4.5 with 50ｵ hydrochloric acid (HCl).  
The ﬁltrate was subjected to a synthetic adsorbent 
Diaion HP20 (Mitsubishi Chemical Co.,  Tokyo,  
Japan) column and the peptides adsorbed were eluted 
with 80ﾝ100ｵ ethanol.  The elution was concentrated 
by an evaporator at 40℃,  and then spray-dried to 
powder.
　 Preparation of HP20-column fractions of 
RJPH. The peptides from RJP were sequentially 
eluted with about 3,000ml of 20, 40, 60, 80 and 100ｵ 
methanol,  monitoring the absorbance at 275nm.  The 
Frs were prepared as follows: aqueous washing,  Fr 
1＋Fr 2; 20ｵ methanol elution,  Fr 3; 40ｵ metha-
nol elution,  Fr 4; 60ｵ methanol elution,  Fr 5; 80ｵ 
methanol elution,  Fr 6; and 100ｵ methanol elution,  
Fr 7.  Each Fr was concentrated using an evaporator 
at 40℃,  followed by freeze drying,  and the yields of 
the Frs were calculated.
　 Measurement of ACE inhibitory activity.
ACE inhibitory activity was assayed according to the 
method of Lieberman,  with some modiﬁcations [14].  
In short,  hippuric acid released from hippuryl-L-his-
tidyl-L-leucine by ACE was extracted with ethyl ace-
tate,  and the concentration was measured by HPLC.  
The ACE inhibitory activity of each substance (ｵ) 
was measured at the concentration of 0.5mg/ml.
　 Molecular weight (MW) distribution. High 
performance gel ﬁltration chromatography was per-
formed with a Shimadzu LC-10A system (Shimadzu 
Co.,  Kyoto,  Japan) under the following condi-
tions: column,  TSK 2000SWXL (7.8mm I.D.×30cm,  
Tohso Co.,  Tokyo,  Japan); mobile phase,  0.1ｵ 
TFA-containing 45ｵ acetonitrile; ﬂow rate,  1ml/
min; column oven temperature,  25℃; detection,  UV 
220nm.  The MW distribution was determined from 
the calibration curve plotted from the correlation 
between peptide and small MW-protein markers and 
the elution time.
　 Measurement of blood pressure. Blood 
pressure was measured by a direct measuring method 
through the left carotid artery under thiobutabarbital 
sodium (Inactin®; Wako,  Ltd.,  Osaka,  Japan) anes-
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thesia (120mg/kg, i.p.) using an amplifier 
(AP-641G; Nihon Kohden Co.,  Tokyo,  Japan) and a 
pressure transducer (TY-400T; Nihon Kohden Co.,  
Tokyo,  Japan).  For intravenous injection,  5 rats 
were used in each group,  and test substances were 
injected into the femoral vein at a rate of 0.05ml/min.  
Blood pressure and heart rate were measured for 
30min after injection.  The ED20 value was deﬁned as 
the dose decreasing the systolic blood pressure by 
20mmHg.  For oral administration,  7 rats were used 
in each group.  The substances were administered at a 
volume of 10ml/kg.  Blood pressure and heart rate 
were measured for 24h after administration.
　 Statistical analysis. Values are the means±
standard error of the means (S.E.M.).  Paired-t test 
and one-way analysis of variance followed by Dunnettʼs 
multiple comparison test were used to analyze the 
hypotensive eﬀects by intravenous and oral adminis-
tration,  respectively.  Values of p＜0.05 were consid-
ered to indicate statistical signiﬁcance.
Results
　 Preparation of HP20 fractions. The chro-
matogram of HP20-column fractionation of RJPH 
using 0,  20,  40,  60,  80 and 100ｵ methanol is shown 
in Fig.  1.  The yields,  ACE inhibitory activity and 
contribution rate (yield×ACE inhibitory activity of 
each Fr/ACE inhibitory activity of RJPH) of Fr 1ﾝ
Fr 7 are shown in Table 1.  The yield of Fr 5 was the 
highest,  followed by Fr 4.  The yield of Fr 7 was very 
low.  The ACE inhibitory activity of Fr 4 was the 
highest,  followed by Fr 5 and Fr 3.  The ACE inhibi-
tory activitiy of Fr 1＋Fr 2 was very low.  There was 
no signiﬁcant correlation between the MWs of RJPH 
in HP20 fractions and their ACE inhibitory activities.  
The inhibitory activity of RJPH before HP20 frac-
tionation was 49.6±4.3ｵ.  The contribution ratio of 
Fr 5 was the highest,  followed by Fr 4,  Fr 3 and Fr 
6.  The contribution ratios of Fr 1＋Fr 2 and Fr 7 
were very low.  The MWs of RJPH and Fr 1ﾝFr 7 
were almost all distributed from 100 to 5,000,  and the 
MWs of the fractions increased in order from Fr 1 to 
Fr 7 (Fig.  2).
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Table 1　 Yields,  ACE inhibitory activity and contribution ratio of 
fractions separated from royal jelly protein hydrolysate
Fraction Yield
(%)
ACE inhibitory 
activity (%)
Contribution ratio
(%)
RJPH － 49.6± 4.3 －
Fr 1＋Fr 2 16.5±12.1 10.0± 5.2 3.3
Fr 3 14.8± 2.0 59.1± 4.0 17.6
Fr 4 21.6± 2.4 65.0± 3.7 28.2
Fr 5 27.0± 1.9 59.8± 1.9 32.5
Fr 6 15.1± 2.7 44.8± 0.4 13.6
Fr 7  0.5± 0.1 38.8±13.6 0.4
Values are the means±S.E.M (n＝3).  The ACE inhibitory activity 
of each substance was measured at the concentration of 0.5mg/
ml.
Fr,  fraction; RJPH,  royal jelly protein hydrolysate.
Contribution ratio: yield×ACE inhibitory activity of each Fr/ACE 
inhibitory activity of RJPH.
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Fig. 1　 Chromatogram of royal jelly protein hydrolysate fractionated by methanol-stepwise elution using an HP20 column
Fr,  fraction; MeOH,  methanol.
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　 Hypotensive eﬀects by intravenous adminis-
tration. When Fr 3ﾝFr 6 were administered 
intravenously,  systolic blood pressure decreased in a 
transient and dose-dependent manner,  reaching the 
lowest level 1min after administration and recovering 
to the previous level within 5min. Signiﬁcant decreases 
of Fr 3 and Fr 4 were observed at doses of 10,  30 
and 100mg/kg.  Fr 5 and Fr 6 showed signiﬁcant 
eﬀects at doses of 30 and 100mg/kg (Table 2).  
However,  the hypotensive eﬀects of Fr 3 and Fr 4 
were slightly higher than those of Fr 5 and Fr 6,  
almost the same ED20 values were observed in Fr 3ﾝ
Fr 6. RJPH also signiﬁcantly and transiently decreased 
blood pressure at doses of 10,  30 and 100mg/kg.  
The eﬀect was slightly lower than those of Fr 3ﾝFr 6,  
but almost the same ED20 values were observed in 
RJPH and Fr 3ﾝFr 6.  There was no correlation 
between the MWs of Fr 3ﾝFr 6 and their hypotensive 
eﬀects.  Transient hypotensive activities were also 
observed by Ile-Tyr at a dose of 10mg/kg,  but this 
eﬀect was not signiﬁcant.  Heart rates were not 
remarkably aﬀected by the intravenous administra-
tions of RJPH,  Fr 3ﾝFr 6 and Ile-Tyr (Table 2).
　 Hypotensive eﬀects by oral administration.
The time course of systolic blood pressure by oral 
administrations of RJP,  Ile-Tyr,  RJPH and Fr 3ﾝ
Fr 6 is shown in Fig. 3.  Blood pressure slowly 
decreased with time by about 20mmHg from the previ-
ous level after 8h in the control group.  Almost identi-
cal changes were observed in the RJP at a dose of 
1,000mg/kg.  Ile-Tyr at a dose of 300mg/kg had no 
signiﬁcant eﬀect,  but Ile-Tyr at a dose of 1,000mg/
kg signiﬁcantly decreased blood pressure at 3h after 
administration.  RJPH and Fr 3ﾝFr 6 showed hypo-
tensive eﬀects in a dose-dependent manner at doses of 
300 and 1,000mg/kg.  At a dose of 300mg/kg,  RJPH,  
Fr 3,  Fr 4 and Fr 6 had no signiﬁcant eﬀect,  but Fr 
5 showed a signiﬁcant eﬀect after 8h.  On the other 
hand,  RJPH at a dose of 1,000mg/kg decreased blood 
pressure gradually with time and a signiﬁcant decrease 
was observed 7 and 8h after administration.  Fr 3 at 
a dose of 1,000mg/kg decreased blood pressure at 2ﾝ
4h after administration,  reaching the maximum hypo-
tensive eﬀect at 3h; this eﬀect was statistically sig-
niﬁcant.  Fr 4 at a dose of 1,000mg/kg also decreased 
blood pressure at 3ﾝ6h,  reaching the lowest level at 
5h.  A signiﬁcant eﬀect was observed after 4 and 5h.  
Fr 5 at a dose of 1, 000mg/kg caused a gradual 
decrease in blood pressure after administration,  with 
the lowest blood pressure occurring after 8h; the 
results after 7 and 8h were statistically signiﬁcant.  
Fr 6 at a dose of 1,000mg/kg decreased blood pres-
sure at 4ﾝ8h after administration,  showing a signiﬁ-
cant and maximum decrease after 8h.  RJPH caused a 
long-lasting hypotensive eﬀect in proportion to the 
magnitude of the MWs of RJPH fractions.  Heart 
rates were not markedly aﬀected by the oral adminis-
trations of RJPH,  Fr 3ﾝFr 6 and Ile-Tyr (Fig.  4).
Discussion
　 In the present study,  it was found that the yields 
of Fr 3 (20ｵ methanol elution),  Fr 4 (40ｵ methanol 
elution),  Fr 5 (60ｵ methanol elution) and Fr 6 (80ｵ 
methanol elution) were high,  and accounted for about 
90ｵ of RJPH.  On the other hand,  the ACE inhibi-
tory activity of these fractions was also high.  Contri-
bution ratios,  which indicate the rate of ACE inhibi-
tory activity in each Fr to that of RJPH,  were also 
high in Fr 4 and Fr 5,  accounting for about 60ｵ of 
RJPH.  From these ﬁndings,  it was thought that 
active components of RJPH were dissolved in 20ﾝ
80ｵ methanol.  As described above,  the MWs of 
RJPH and Fr 1ﾝFr 7 were distributed from 100 to 
5,000,  and the MWs were successively higher from Fr 
1 to Fr 7.  In other words,  each Fr separated from 
RJPH was eluted with an increase in the methanol 
concentration.  It is well known that Fr 3 contains 
many low MW peptides,  such as dipeptide and tripep-
tide,  Fr 4 contains larger peptides and Fr 5 and Fr 6 
contain peptides consisting of 6 or more amino acids.
　 It was also found that intravenous injection of 
RJPH and Fr 3ﾝFr 6 caused a dose-dependent and 
transient hypotensive eﬀect,  and the hypotensive 
eﬀects of these Frs were similar.  Ile-Tyr used as a 
reference drug also showed a transient hypotensive 
eﬀect,  and similar short transient hypotensive eﬀects 
have been reported after intravenous injection of Ile-
Lys-Pro (10mg/kg [15]),  Ile-Tyr (10mg/kg [15]),  
and Leu-Arg-Pro (30mg/kg [16]).  The ﬁndings sug-
gest that these peptides were incorporated into the 
blood,  and were rapidly (within 5min) metabolized and 
degraded by peptidase in the blood.
　 Oral administration of Fr 3,  Fr 4,  Fr 5 and Fr 6 
at a dose of 1,000mg/kg also resulted in lower blood 
pressure,  and a signiﬁcant hypotensive eﬀect was 
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Fig. 2　 High performance gel ﬁltration chromatography of royal jelly protein hydrolysate and its fractions
Fr,  fraction; RJPH,  royal jelly protein hydrolysate.
Table 2　 Eﬀects of intravenous injections of royal jelly protein hydrolysate and its fractions on blood pressure and heart rate in anesthe-
tized SHR
Test sample Dose(mg/kg, i.v.)
Systolic blood pressure
(% of previous value) ED20
 (mg/kg)
Heart rate
(% of previous value)
After 1min After 5min After 1min After 5min
Control － 100.2±1.0　　  99.3±0.1 －  98.2±0.4 98.6±0.6
RJPH  10  94.0±1.4＊　 103.4±3.0 18.9 100.4±0.1 98.2±1.6
 30  83.9±2.7＊＊ 111.8±3.2 100.8±0.2 101.2±1.5
100  81.4±4.7＊　 114.1±2.8 100.9±0.1 102.7±0.9
Fr 3  10  92.6±2.3＊　  99.9±1.1 18.7 100.8±0.7 99.5±0.3
 30  79.7±5.8＊　 105.7±3.7  97.9±2.3 98.0±0.5
100  67.8±1.5＊＊ 102.1±2.1 100.8±0.7 102.7±2.1
Fr 4  10  91.2±2.7＊　  99.3±2.1 19.3 101.1±0.3 99.8±0.7
 30  81.3±5.2＊　 105.0±0.9 101.4±0.5 101.9±0.9
100  75.5±2.3＊＊ 104.6±2.3 101.9±0.6 101.8±1.5
Fr 5  10  93.6±2.1　　 101.2±0.7 20.2 100.8±0.4 99.2±0.5
 30  85.1±4.0＊　 101.7±2.4 101.6±0.4 99.9±1.4
100  75.6±3.9＊＊ 102.3±1.2  99.2±1.8 100.0±1.8
Fr 6  10  93.1±3.2　　 107.7±3.7 19.6  97.8±2.9 100.2±1.9
 30  83.6±2.0＊＊ 105.8±2.3 100.4±2.8 96.9±1.2
100  75.5±0.9＊＊ 112.1±1.2 101.4±0.9 100.4±0.6
Ile-Tyr  10  87.4±6.8　　 104.2±1.0 －  99.7±0.2 99.6±1.1
Values are the means±S.E.M. of 5 rats.  The control group was injected with physiological saline.  SHR were anesthetized before mea-
surement of blood pressure and heart rate.  RJPH,  royal jelly protein hydrolysate; ED20 (mg/kg),  the dose to decrease systolic blood 
pressure by 20mmHg.  ＊p＜0.05 (v.s.  previous level,  paired t-test),  ＊＊p＜0.01 (v.s.  previous level,  paired t-test).
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observed after 3h in Fr 3,  4ﾝ5h in Fr 4,  7ﾝ8h in 
Fr 5 and 8h in Fr 6.  These ﬁndings indicate that the 
time of decrease in blood pressure was delayed with 
an increase in the MWs of these peptides.  It is well 
recognized that some short-acting peptides,  such as 
dipeptide and tripeptide,  are absorbed directly,  and 
many long peptides are ﬁrst digested and subsequently 
absorbed as shorter fragment peptides or amino acids 
[17],  which is the reason why long peptides such as 
Fr 5 and Fr 6 showed a delayed hypotensive eﬀect.  
RJPH also caused a potent hypotensive eﬀect 1ﾝ8h 
after administration,  and a signiﬁcant diﬀerence was 
observed at 7 and 8h.  The hypotensive eﬀect of 
RJPH was attributed to trypsin treatment of RJP,  
because RJP alone did not show such an eﬀect.  By 
comparing the hypotensive eﬀect of RJPH and Fr 3 
and Fr 6,  it was found that the hypotensive pattern of 
RJPH closely resembled to the combined pattern of 
Fr 3ﾝFr 6.
　 Crude royal jelly contains protein of about 13ｵ,  
which is about 1/6 the content of RJP.  However,  as 
shown in Fig.  3,  RJP showed no hypotensive eﬀect 
even at a dose of 1,000mg/kg.  RJPH is a puriﬁed 
substance produced by trypsin hydrolyzation and 
desalting of RJP,  and this compound caused a hypo-
tensive eﬀect at a dose of 1,000mg/kg.  It seems 
likely,  therefore,  that crude royal jelly showed no 
hypotensive eﬀect even at a dose of 6,000mg/kg.
　 On the other hand,  Ile-Tyr,  which was used as a 
reference,  caused a slight hypotensive eﬀect 3h after 
oral administration at a dose of 300mg/kg,  but it was 
not signiﬁcant.  Fujita et al.  [15] reported much more 
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Fig. 3　 Eﬀects of oral administration of royal jelly protein,  Ile-Tyr,  royal jelly protein hydrolysate and Fr 3 and Fr 6 on blood pressure in 
anesthetized SHR.  Values are the means±S.E.M.  of 7 rats.  SHR were anesthetized before measurement of blood pressure.  RJP,  royal 
jelly protein; RJPH,  royal jelly protein hydrolysate; Fr,  fraction.  ＊p＜0.05 (v.s. control,  Dunnettʼs multiple comparison test),  ＊＊p＜0.01 
(v.s. control,  Dunnettʼs multiple comparison test).
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potent eﬀects of Ile-Tyr; in their study,  Ile-Tyr 
induced signiﬁcant hypotension even at a dose of 
60mg/kg.  At present,  we are uncertain as to why 
Ile-Tyr caused such a potent hypotensive eﬀect in 
their study,  but the discrepancy may be related to 
diﬀerences in the methods used to measure blood 
pressure.
　 In the present work,  RJPH caused a long-lasting 
hypotensive eﬀect in proportion to the magnitude of 
MWs of RJPH fractions.  From these ﬁndings,  it can 
be concluded that the long-lasting hypotensive eﬀect of 
RJPH is related to the MW of its ACE inhibitory 
peptides and the time required to digest them,  and 
that Fr 4 and Fr 5 make the main contributions to the 
persistent hypotensive eﬀect of orally administered 
RJPH.
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